Psychedelics or SSRI's?

This new research looks at the effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder.

The study found that six-week intensive treatments with either psilocybin or escitalopram (with psychological support) for MDD were associated with long-term improvements in depressive symptom severity. The greater degree of improvement in the PT arm at follow-up on psychosocial functioning, meaning in life, and psychological connectedness suggests warrant future research.

Read more

Psilocybin for Inner Healing Depression

The journey to healing from depression often demands more than just symptom management; it requires a deep, inner transformation that addresses the root of emotional distress.

This inner healing process is crucial for those suffering from depression, as it can lead to more profound and lasting recovery.

Emerging research on psychedelics, particularly psilocybin, is shedding light on how these substances might facilitate this essential aspect of healing, offering new hope for individuals struggling with depression.

Read more

Promising Results for Depression Treatment with Microdosing LSD

MindBio Therapeutics Corp. (CSE) has recently unveiled promising durability data from its Phase 2A clinical trials, which tested MB22001, the company’s innovative self-administered, take-home microdose of Lysergic Acid Diethylamide (LSD), as a treatment for depression.

This development underscores MindBio’s commitment to advancing psychedelic medicine as a viable option for mental health treatment.

Read more

The Importance of Therapy!

A study published recently in PLOS One suggests that therapy may, in fact, play an important role in psilocybin-assisted therapy for major depressive disorder.

In a study of 24 participants with MDD, those who reported stronger alliance, or “sense of collaboration between patient and client,” with their therapist were more likely to show improvements in their depression scores after two psilocybin dosing sessions.

Stronger ratings of therapeutic alliance during the study’s final preparation session were correlated with improved depression scores for 12 months after the study.

Read more

Next-Gen Psilocybin

Cybin, a biotech company working on next-generation psychedelic treatments, announced remarkable results from its Phase 2 clinical trial using a proprietary version of deuterated psilocybin for the treatment of depression.

CYB003 is a next-generation psilocybin designed to provide a faster onset of action and to reduce the duration of effects, ultimately thinning the financial barrier to access of this medicine in a medical setting.

The trial’s interim data demonstrated “rapid, robust, and clinically significant reduction of depression symptoms” three weeks after a single 12mg dose of CYB003.

Read more

Psilocybin, Cancer and Depression

The HOPE trial (A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients with Cancer) is an Institutional Review Boards-approved open-label feasibility and safety pilot study examining psilocybin-assisted group therapy in cancer patients with a DSM-5 depressive disorder (including major depressive disorder as well as adjustment disorder with depressed mood).

This pilot study demonstrated the safety, feasibility, and possible efficacy of psilocybin-assisted group therapy for cancer patients dealing with depressive symptoms.

Read more